NYU Long Island School of Medicine, NYU Langone Hospital - Long Island, Department of Pathology, 11501, USA.
NYU Long Island School of Medicine, NYU Langone Hospital - Long Island, Department of Pathology, 11501, USA.
Hum Pathol. 2021 Mar;109:59-68. doi: 10.1016/j.humpath.2020.11.015. Epub 2020 Dec 8.
Although coronavirus disease 2019 (COVID-19) is transmitted via respiratory droplets, there are multiple gastrointestinal and hepatic manifestations of the disease, including abnormal liver-associated enzymes. However, there are not many published articles on the pathological findings in the liver of patients with COVID-19. We collected the clinical data from 17 autopsy cases of patients with COVID-19 including age, sex, Body mass index (BMI), liver function test (alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), alkaline phosphatase (ALP), direct bilirubin, and total bilirubin), D-dimer, and anticoagulation treatment. We examined histopathologic findings in postmortem hepatic tissue, immunohistochemical (IHC) staining with antibody against COVID-19 spike protein, CD68 and CD61, and electron microscopy. We counted the number of megakaryocytes in liver sections from these COVID-19-positive cases. Abnormal liver-associated enzymes were observed in 12 of 17 cases of COVID-19 infection. With the exception of three cases that had not been tested for D-dimer, all 14 patients' D-dimer levels were increased, including the cases that received varied doses of anticoagulation treatment. Microscopically, the major findings were widespread platelet-fibrin microthrombi, steatosis, histiocytic hyperplasia in the portal tract, mild lobular inflammation, ischemic-type hepatic necrosis, and zone 3 hemorrhage. Rare megakaryocytes were found in sinusoids. COVID-19 IHC demonstrates positive staining of the histiocytes in the portal tract. Under electron microscopy, histiocyte proliferation is present in the portal tract containing lipid droplets, lysosomes, dilated ribosomal endoplasmic reticulum, microvesicular bodies, and coronavirus. The characteristic findings in the liver of patients with COVID-19 include numerous amounts of platelet-fibrin microthrombi, as well as various degrees of steatosis and histiocytic hyperplasia in the portal tract. Possible mechanisms are also discussed.
虽然 2019 年冠状病毒病(COVID-19)通过呼吸道飞沫传播,但该疾病有多种胃肠道和肝脏表现,包括肝相关酶异常。然而,关于 COVID-19 患者肝脏的病理发现,发表的文章并不多。我们收集了 17 例 COVID-19 尸检患者的临床数据,包括年龄、性别、体重指数(BMI)、肝功能试验(丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、直接胆红素和总胆红素)、D-二聚体和抗凝治疗。我们检查了死后肝组织的组织病理学发现,用针对 COVID-19 刺突蛋白、CD68 和 CD61 的抗体进行免疫组织化学(IHC)染色,并进行电子显微镜检查。我们计算了这些 COVID-19 阳性病例肝组织切片中的巨核细胞数量。在 17 例 COVID-19 感染病例中,有 12 例出现肝相关酶异常。除了 3 例未检测 D-二聚体的病例外,所有 14 例患者的 D-二聚体水平均升高,包括接受不同剂量抗凝治疗的病例。显微镜下,主要发现是广泛的血小板-纤维蛋白微血栓形成、脂肪变性、门脉区组织细胞增生、轻度小叶炎症、缺血性肝坏死和 3 区出血。窦状隙中罕见巨核细胞。COVID-19 IHC 显示门脉区组织细胞呈阳性染色。在电子显微镜下,门脉区存在组织细胞增生,其中含有脂滴、溶酶体、扩张的核糖体内质网、微泡体和冠状病毒。COVID-19 患者肝脏的特征性发现包括大量血小板-纤维蛋白微血栓形成,以及门脉区不同程度的脂肪变性和组织细胞增生。还讨论了可能的机制。